Satoshi Sugiyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Satoshi Sugiyama has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Akira Nishiyama
Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan
1 shared publication - Eri Muso
Division of Nephrology and Dialysis, Kitano Hospital, Osaka, Japan
1 shared publication - Hideki Kimura
Department of Clinical Laboratory, University of Fukui Hospital, Fukui, Japan
1 shared publication - Hiroaki Oda
Laboratory of Nutritional Biochemistry, Nagoya University, Nagoya 464-8601, Japan
1 shared publication - Hirokazu Honda
Department of Nephrology, Showa Medical University Graduate School of Medicine, Tokyo, Japan
1 shared publication - Hiroshi Sato
Department of Obstetrics and Gynecology Hyogo Prefectural Amagasaki General Medical Center Amagasaki Japan
1 shared publication
Latest Publications
- 1 January 2022
- Published by Elsevier in Journal of Molecular Graphics and Modelling
- Vol. 110, 108047
Proposal of selective inhibitor for bacterial zinc metalloprotease: Molecular mechanics and ab initio molecular orbital calculations
- 1 January 2022
- Published by Elsevier in Journal of Molecular Graphics and Modelling
- Vol. 110, 108047
Proposal of selective inhibitor for bacterial zinc metalloprotease: Molecular mechanics and ab initio molecular orbital calculations
- Open Access
- 31 May 2021
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 26 (1) , 220-228
Favorable therapeutic efficacy of low‐density lipoprotein apheresis for nephrotic syndrome with impaired renal function
Many reports have shown the therapeutic efficacy of LDL apheresis (LDL‐A) in drug‐resistant nephrotic syndrome (NS) for improvement of heavy proteinuria and severely impaired renal function. To obtain comprehensive results in a large number of cases, a post hoc analysis of the Prospective Observational survey on the Long‐Term Effects of the LDL‐Apheresis on the Drug Resistant Nephrotic Syndrome (POLARIS) study was performed by stratifying enrolled cases according to the pretreatment estimated glomerular filtration rate (eGFR) levels indicating normal (N) (≥60 ml/min/1.73 m2), moderately impaired (M) (≥30 to 2), and severely impaired (S) (2) renal function. Significant improvements of proteinuria and renal function were found in Group N and, most interestingly, in Group M. A tendency for improvement in proteinuria was found in Group S. Most cases in all groups had not entered end‐stage renal disease at 2 years after LDL‐A treatment. These results suggest that LDL‐A has therapeutic efficacy even in cases in which renal function has declined to 30 ml/min/1.73 m2.
- 31 May 2021
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 26 (1) , 220-228
Open AccessFavorable therapeutic efficacy of low‐density lipoprotein apheresis for nephrotic syndrome with impaired renal function
Many reports have shown the therapeutic efficacy of LDL apheresis (LDL‐A) in drug‐resistant nephrotic syndrome (NS) for improvement of heavy proteinuria and severely impaired renal function. To obtain comprehensive results in a large number of cases, a post hoc analysis of the Prospective Observational survey on the Long‐Term Effects of the LDL‐Apheresis on the Drug Resistant Nephrotic Syndrome (POLARIS) study was performed by stratifying enrolled cases according to the pretreatment estimated glomerular filtration rate (eGFR) levels indicating normal (N) (≥60 ml/min/1.73 m2), moderately impaired (M) (≥30 to 2), and severely impaired (S) (2) renal function. Significant improvements of proteinuria and renal function were found in Group N and, most interestingly, in Group M. A tendency for improvement in proteinuria was found in Group S. Most cases in all groups had not entered end‐stage renal disease at 2 years after LDL‐A treatment. These results suggest that LDL‐A has therapeutic efficacy even in cases in which renal function has declined to 30 ml/min/1.73 m2.